Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer’s Disease via Neuroinflammation and Ferroptosis
Authors:
Open Access
- 30 October 2023
- journal article
- review article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 96 (3) , 927-945
Abstract
Alzheimer’s disease (AD) is the main cause of dementia in older age. The prevalence of AD is growing worldwide, causing a tremendous burden to societies and families. Due to the complexity of its pathogenesis, the current treatment of AD is not satisfactory, and drugs acting on a single target may not prevent AD progression. This review summarizes the multi-target pharmacological effects of thiazolidinediones (TZDs) on AD. TZDs act as peroxisome proliferator-activated receptor gamma (PPAR γ) agonists and long-chain acyl-CoA synthetase family member 4 (ACSL4) inhibitors. TZDs ameliorated neuroinflammation and ferroptosis in preclinical models of AD. Here, we discussed recent findings from clinical trials of pioglitazone in the treatment of AD, ischemic stroke, and atherosclerosis. We also dissected the major limitations in the clinical application of pioglitazone and explained the potential benefit of pioglitazone in AD. We recommend the use of pioglitazone to prevent cognitive decline and lower AD risk in a specific group of patients.Keywords
This publication has 171 references indexed in Scilit:
- Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cellsJournal of Neuroinflammation, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal functionJournal of Neuroinflammation, 2012
- Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like TanglesJournal of Biological Chemistry, 2011
- Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's DiseaseCell, 2010
- Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau PathologyNeuropsychopharmacology, 2010
- Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer CellsChemistry & Biology, 2008
- The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspectiveJournal of Neuroinflammation, 2008
- Macrophage-specific PPARγ controls alternative activation and improves insulin resistanceNature, 2007
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991